دورية أكاديمية
Successful Treatment With the Oral Factor Xa Inhibitor Edoxaban in Heparin-Induced Thrombocytopenia With Thrombosis.
| العنوان: | Successful Treatment With the Oral Factor Xa Inhibitor Edoxaban in Heparin-Induced Thrombocytopenia With Thrombosis. |
|---|---|
| المؤلفون: | Porres-Aguilar M; Department of Internal Medicine, Texas Tech University Health Sciences Center/Paul L. Foster School of Medicine, El Paso, TX, USA., Najera C; Department of Internal Medicine, Texas Tech University Health Sciences Center/Paul L. Foster School of Medicine, El Paso, TX, USA., Mares AC; Yale University School of Medicine, New Haven, CT, USA., Benzidia I; Vascular Medicine Unit, Department of Thoracic, Cardiovascular Surgery and Vascular Medicine, CHU Reunion-Site Nord, Saint Denis, France., Prakash S; Department of Internal Medicine, Texas Tech University Health Sciences Center/Paul L. Foster School of Medicine, El Paso, TX, USA., Crichi B; Department of Internal Medicine, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. |
| المصدر: | Angiology [Angiology] 2023 Dec 28, pp. 33197231225291. Date of Electronic Publication: 2023 Dec 28. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Sage Publications Country of Publication: United States NLM ID: 0203706 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1940-1574 (Electronic) Linking ISSN: 00033197 NLM ISO Abbreviation: Angiology Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Thousand Oaks, CA : Sage Publications Original Publication: New York [etc.] Angiology Research Foundation. |
| مستخلص: | Heparin-induced thrombocytopenia with thrombosis (HITT) is a rare immune reaction to the drug heparin that causes increased blood clotting, putting patients at risk for arterial and venous thromboembolism which can have severe consequences. We present a case of HITT successfully treated with the direct oral anticoagulant (DOAC), edoxaban. A 56-year-old man had surgery to remove a colorectal mass. After discharge, he developed chest discomfort, shortness of breath, and low oxygen levels and was diagnosed with a right-sided lobar pulmonary embolism. His platelet count dropped, his tests confirmed a diagnosis of HITT, and he was initially treated with fondaparinux. After showing clinical and laboratory improvement, he was switched to edoxaban. Despite being diagnosed with colonic adenocarcinoma during follow-up, the patient's platelet count returned to normal, and he did not experience any more blood clots or serious bleeding events. The use of DOACs like edoxaban as potential therapies for HITT is promising; further research is being conducted to evaluate their effectiveness, safety, and potential benefits for treating this acquired high-risk thrombophilia. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
| فهرسة مساهمة: | Keywords: direct oral anticoagulants; edoxaban; factor Xa inhibitors; heparin-induced thrombocytopenia; pulmonary embolism; venous thromboembolism |
| تواريخ الأحداث: | Date Created: 20231228 Latest Revision: 20231228 |
| رمز التحديث: | 20231228 |
| DOI: | 10.1177/00033197231225291 |
| PMID: | 38153027 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1940-1574 |
|---|---|
| DOI: | 10.1177/00033197231225291 |